<DOC>
	<DOCNO>NCT01645332</DOCNO>
	<brief_summary>This 2-arm , double-blind , parallel , randomized , placebo-controlled clinical study , 12 week therapy evaluate efficacy safety DLBS3233 improve metabolic control newly diagnose type-2-diabetic patient , measure A1c level , fast 2-hours post-prandial plasma glucose , fast insulin level , HOMA-IR , HOMA-B , adiponectin level , lipid profile , body weight .</brief_summary>
	<brief_title>Efficacy Safety DLBS3233 Subjects With New Onset Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>There two group treatment study receive DLBS3233 placebo DLBS3233 ( lifestyle modification ) 12 week therapy . Clinical physical examination evaluate efficacy safety well measurement fast 2-hour post-prandial plasma glucose level perform baseline every 6-weeks-interval . Other clinical laboratory examination perform baseline end study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject age 1860 year BMI ≥ 18.5 kg/m2 Newly diagnose ( new onset ) type 2 DM subject , define FPG level ≥ 126 mg/dL 2hPG level ≥ 200 mg/dL A1c ≥ 6.5 % ) FPG ≤ 183 mg/dL Hemoglobin level ≥ 10.0 g/dL Serum ALT ≤ 2.5 time upper limit normal Serum creatinine &lt; 1.5 time upper limit normal Female childbearing potential Subjects symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , symptomatic ischemic arterial disease necessitate medical treatment Uncontrolled hypertension ( SBP &gt; 160 mmHg and/or DBP &gt; 100 mmHg ) History renal and/or liver disease History presence clinical evidence malignancy Presence exacerbation chronic illness , severe acute infection , complicate infection Current treatment systemic corticosteroid herbal ( alternative ) medicine Participation intervention trial within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>DLBS3233</keyword>
	<keyword>new onset</keyword>
	<keyword>type-2-diabetes mellitus</keyword>
	<keyword>oral anti-hyperglycemic agent</keyword>
</DOC>